PharmaFocus Today – media

While Da Vinci Remains in “Remote Control” Mode, Cornerstone Robotics Has Evolved to “Autonomous Operation”—A Technological Leap for Domestic Surgical Robots

For over two decades, the Da Vinci system has monopolized the global market for laparoscopic surgical robots, commanding prices as high as 20–30 million RMB per unit. This massive supply gap has created a historic opportunity for domestic alternatives. The globalization strategy of Cornerstone Robotics offers a valuable case study for the industry. In the first half of 2026, overseas shipments of Chinese laparoscopic surgical robots exceeded 154 units, accounting for 81% of the total volume for that period. Specifically, Cornerstone Robotics’ shipment breakdown—comprising four new domestic installations and five new installations across Hong Kong and international markets—clearly demonstrates that the overseas expansion of domestic surgical robots has moved beyond the proof-of-concept stage into a phase of tangible realization involving orders, installations, and clinical application. 01 The Hong Kong Pivot: A “Clinical Touchstone” of High Standards To understand Cornerstone Robotics’ overseas expansion strategy, one must first grasp the strategic importance ...
- Source: drugdu
- 54
- July 31, 2026
Carbamazepine Extended-Release Tablets (II) Receive Drug Registration Certificate

ST Renfu(600079.SH) announced that its subsidiary, Yichang Renfu, recently received a Drug Registration Certificate for Carbamazepine Extended-Release Tablets (II) issued by the National Medical Products Administration. This drug is primarily used to treat epilepsy and trigeminal neuralgia. https://finance.eastmoney.com/a/202607273822088834.html
- Source: drugdu
- 54
- July 31, 2026
Levocarnitine Oral Solution Receives Drug Registration Certificate

Nanfang Finance News, July 28th – Progen PharmaceuticalsThe company announced that its controlling subsidiary, Zhejiang Procon Pharmaceutical Co., Ltd., received a Drug Registration Certificate for Levocarnitine Oral Solution issued by the National Medical Products Administration. This product is used to treat primary systemic carnitine deficiency, and also for the short-term and long-term treatment of secondary carnitine deficiency caused by congenital metabolic abnormalities. https://finance.eastmoney.com/a/202607283823563474.html
- Source: drugdu
- 48
- July 31, 2026
Application for drug registration and marketing authorization of dapagliflozin tablets accepted

People’s Finance News, July 27 – Saisheng PharmaceuticalOn July 27, (300485) announced that its subsidiary, Saier Biotech, recently received an “Acceptance Notice” from the National Medical Products Administration (NMPA) for its application for registration and marketing authorization of dapagliflozin tablets for domestic production. This drug lowers blood sugar by inhibiting renal tubular glucose reabsorption and promoting urinary glucose excretion. Monotherapy carries a low risk of hypoglycemia, does not cause weight gain, has mild gastrointestinal reactions, and may protect pancreatic β-cell function by reducing glucotoxicity. https://finance.eastmoney.com/a/202607273822093693.html
- Source: drugdu
- 46
- July 31, 2026
China Biopharmaceutical and Indonesia’s Tempo Scan establish a joint venture with China Biopharmaceutical holding a 51% stake to expand the Southeast Asian pharmaceutical market

On July 27, China Biopharmaceutical (01177) announced that it had signed a joint venture agreement with Indonesian listed company PT Tempo Scan Pacific Tbk (Tempo Scan) to jointly establish a joint venture company PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI). Sino Biopharmaceutical holds a 51% stake in TCBI, while Tempo Scan holds a 49% stake. The joint venture will combine Sino Biopharmaceutical’s strengths in innovative R&D and product pipeline with Tempo Scan’s localized capabilities in Indonesia, including manufacturing, regulatory registration, market access, sales and marketing, and distribution networks. The announcement stated that both parties are currently advancing multiple specialty drugs and innovative drugs.The registration and listing process has been completed, with some products already approved and several others under review. In addition to commercial cooperation, both parties will continue to explore further cooperation opportunities, including academic exchanges, local clinical development, production technology transfer, and future localized production. The establishment of the ...
- Source: drugdu
- 48
- July 31, 2026
Subsidiary’s application for clinical trial registration of GenSci144 tablets for domestic production approved

People’s Finance News, July 30th – Changchun High & New Technology Industries Group Co., Ltd.(000661) announced on July 30 that its subsidiary, Jinsai Pharmaceutical, recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, and the application for registration of the domestic production of GenSci144 tablets by Jinsai Pharmaceutical has been approved. GenSci144 tablets are an oral small molecule inhibitor targeting the neutral amino acid transporter SLC6A19, independently developed by Jinsai Pharmaceutical. It is registered as a Class 1 chemical drug and is intended for the treatment of chronic kidney disease (CKD). https://finance.eastmoney.com/a/202607303826738322.html
- Source: drugdu
- 42
- July 31, 2026
Degludec Insulin Injection Receives Marketing Approval

On July 30, Dongyangguang Pharmaceutical (06887) announced that its independently developed insulin degludec injection has received marketing approval from the National Medical Products Administration (NMPA). The drug is available in both cartridge and pre-filled injection pen versions. Insulin degludec injection is a fourth-generation long-acting basal insulin analog with a half-life of approximately 25 hours and a duration of action exceeding 42 hours, allowing for once-daily dosing to meet the entire day’s basal insulin requirements. Furthermore, this drug is superior to insulin glargine in terms of glucose-lowering curve stability and the incidence of hypoglycemia. With the launch of insulin degludec injection, the company now offers six insulin products in the Chinese market, covering three major clinical application scenarios: basal, prandial, and premixed insulin. The company is also pursuing international registration for other insulin products to expand its international market share. https://finance.eastmoney.com/a/202607303826929962.html
- Source: drugdu
- 38
- July 31, 2026
The king of valves’ revenue exceeded expectations, with TMTT surging by 47%!

Edwards Life Sciences recently announced its second-quarter results, with revenue of $1.74 billion, a 13.6% year-over-year increase, representing a significant growth.However, it’s worth noting that net profit performance contrasts sharply with revenue growth. Net profit for the period was $241.9 million, a 27.4% year-over-year decline. Nevertheless, looking at each business segment, Edwards’ core business remains solid. As Edwards’ core business, transcatheter aortic valve replacement (TAVR) sales reached $1.3 billion in the second quarter, up 11.3% year-over-year. This business accounts for approximately 75% of the company’s total revenue and remains its absolute pillar. Edwards attributed the growth of TAVR to continued clinical momentum and evidence-based support for active disease management of aortic stenosis. The company specifically highlighted the differentiated advantages of its Sapien TAVR platform, namely the 7-year follow-up data from the PARTNER 3 trial presented at the recent New York Heart Valve Conference, and the latest findings from the EARLY ...
- Source: drugdu
- 62
- July 27, 2026
A neurosurgical robotics company has officially announced its latest appointment!

AiM Medical Robotics recently announced the appointment of Andrew “Andy” Aberdale as the company’s new president and chief financial officer. Founded in 2018, AiM Medical Robotics is a company focused on neurosurgical robots, dedicated to developing surgical robot technologies that enable precise neurosurgical procedures to be performed directly under magnetic resonance imaging. Its platform utilizes a combination of intraoperative real-time magnetic resonance imaging and robot guidance in neurosurgical systems to ensure precise implantation of neurostimulation electrodes for Parkinson’s disease patients. The platform has also been extended to a range of craniocerebral surgeries, such as biopsies, tumor ablation, and targeted intracranial delivery of novel therapies. It is understood that Andy, the newly appointed leader, has over thirty years of experience in operations and finance leadership. His past experience includes successfully commercializing early-stage startups and achieving smooth exits, as well as executing high-value exits and driving rapid organizational growth. According to the ...
- Source: drugdu
- 63
- July 27, 2026
Despite positive news, the stock price fell after Watson Bio’s bivalent HPV vaccine received marketing authorization in Tanzania.

On July 23, an announcement from Watson Bio ( 300142.SZ ) attracted market attention. The bivalent HPV vaccine WALRINVAX (vial specification) produced by the subsidiary Yuxi Zerun has obtained a drug registration certificate issued by the Tanzania Medicines and Medical Devices Authority and is approved for marketing in the local market. This is not a simple news story about “going global”. Watson Bio’s Tanzanian registration certificate is both an “entry ticket” to the African market and a “must-answer question” regarding its commercialization capabilities. The positive announcement contradicted the stock price movement. On July 23, Watson Bio closed at 13.26 yuan, down 1.70%. image.png On July 24, the decline further widened, hitting a low of 12.72 yuan during the session. By the morning close, the stock was trading at 12.83 yuan, a drop of 3.24%. Other data showed that the stock price once fell to 12.75 yuan, a drop of as ...
- Source: drugdu
- 58
- July 27, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.